Oxoisoaporphine as Potent Telomerase Inhibitor

被引:13
作者
Wei, Zu-Zhuang [1 ]
Qin, Qi-Pin [1 ]
Chen, Jia-Nian [1 ]
Chen, Zhen-Feng [1 ]
机构
[1] Guangxi Normal Univ, Sch Pharm & Chem, State Key Lab Chem & Mol Engn Med Resources, 15 Yucai Rd, Guilin 541004, Peoples R China
基金
中国国家自然科学基金;
关键词
oxoisoaporphine; telomerase; molecular docking; G-QUADRUPLEX DNA; TUMOR-CELL APOPTOSIS; PLATINUM(II) COMPLEX; MITOCHONDRIAL FUNCTIONS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; STABILIZATION; RNA; DERIVATIVES; INDUCTION;
D O I
10.3390/molecules21111534
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Two compounds previously isolated from traditional Chinese medicine, Menispermum dauricum (DC), 6-hydroxyl-oxoisoaporphine (H-La), and 4,6-di(2-pyridinyl) benzo[h] isoindolo[4,5,6-de] quinolin-8(5H)-one (H-L-b), were known to have in vitro antitumor activity and to selectively bind human telomeric, c-myc, and bcl-2 G-quadruplexes (G4s). In this study, the binding properties of these two compounds to telomerase were investigated through molecular docking and telomeric repeat amplication protocol and silver staining assay (TRAP-silver staining assay). The binding energies bound to human telomerase RNA were calculated by molecular docking to be 6.43 and 9.76 kcal/mol for H-L-a and H-L-b, respectively. Compared with H-L-a, the ligand H-L-b more strongly inhibited telomerase activity in the SK-OV-3 cells model.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Inhibition of Human Tumor Cell Proliferation by the Telomerase Inhibitor TELIN
    Kakiuchi, Yasutaka
    Oyama, Mika
    Nakatake, Mayuka
    Okamoto, Yayoi
    Kai, Hirofumi
    Arima, Hidetoshi
    Murofushi, Hiromu
    Murakami-Murofushi, Kimiko
    CYTOLOGIA, 2010, 75 (02) : 177 - 183
  • [32] Characterization and antitumor activity of triethylene tetramine, a novel telomerase inhibitor
    Liu, Jianhui
    Guo, Lixia
    Yin, Fei
    Zheng, Xuxu
    Chen, Gang
    Wang, Yun
    BIOMEDICINE & PHARMACOTHERAPY, 2008, 62 (07) : 480 - 485
  • [33] The hTERTα splice variant is a dominant negative inhibitor of telomerase activity
    Colgin, LM
    Wilkinson, C
    Englezou, A
    Kilian, A
    Robinson, MO
    Reddel, RR
    NEOPLASIA, 2000, 2 (05): : 426 - 432
  • [34] IMETELSTAT SODIUM Telomerase-Targeting Oligonucleotide Inhibitor Oncolytic
    Haddley, K.
    DRUGS OF THE FUTURE, 2012, 37 (02) : 111 - 118
  • [35] TELOMERASE RNA AND TELOMERASE ACTIVITY IN TROPHOBLASTIC TUMORS
    郑伟
    石一复
    谢幸
    徐建云
    程琪
    沈敏
    Journal of Zhejiang University Science, 2000, (02) : 85 - 89
  • [36] Functional Interactions of Kluyveromyces lactis Telomerase Reverse Transcriptase with the Three-Way Junction and the Template Domains of Telomerase RNA
    Al-Shareef, Wasif
    Brown, Yogev
    Bryan, Christopher
    Shuvaeva, Elena
    Bsoul, Shhadeh
    Greenman, Raanan
    Kabaha, Majdi M.
    Ulyanov, Nikolai B.
    Skordalakes, Emmanuel
    Tzfati, Yehuda
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
  • [37] Development of a potent peptide inhibitor of estrogen receptor α
    Qin, Xuan
    Zhao, Hui
    Jiang, Yanhong
    Yin, Feng
    Tian, Yuan
    Xie, Mingsheng
    Ye, Xiyang
    Xu, Naihan
    Li, Zigang
    CHINESE CHEMICAL LETTERS, 2018, 29 (07) : 1160 - 1162
  • [38] Divalent hammerhead ribozyme targeting template region of human telomerase RNA has potent cleavage activity, but less inhibitory activity on telomerase
    Yokoyama, Y
    Wan, X
    Takahashi, Y
    Shinohara, A
    Liulin, T
    Tamaya, T
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2002, 405 (01) : 32 - 37
  • [39] Synthesis of benzothiazole derivatives as a potent α-glucosidase inhibitor
    Gollapalli, Mohammed
    Taha, Muhammad
    Javid, Muhammad Tariq
    Almandil, Noor Barak
    Rahim, Fazal
    Wadood, Abdul
    Mosaddik, Ashik
    Ibrahim, Mohamed
    Alqahtani, Mohammed A.
    Bamarouf, Yasser A.
    BIOORGANIC CHEMISTRY, 2019, 85 : 33 - 48
  • [40] Characterization of In Vitro G-Quadruplex Formation of Imetelstat Telomerase Inhibitor
    Carloni, Laure-Elie
    Wechselberger, Rainer
    De Vijlder, Thomas
    NUCLEIC ACID THERAPEUTICS, 2021, 31 (05) : 341 - 350